Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The general aim of this study is to obtain long-term safety and tolerability data on
pramipexole ER, in daily doses from 0.375mg to 4.5mg once daily (q.d), in patients who have
previously completed a pramipexole double-blind study in early PD (248.524(NCT00479401) or
248.636(NCT00558025) trial).